|
Progress-free survival
|
|
Age (≤ 50 vs > 50)
|
1.184 (0.742–1.889)
|
0.479
| | |
|
Sex (Female vs Male)
|
0.925 (0517–1.655)
|
0.792
| | |
|
Chemotherapy cycles (< 4 vs ≥ 4)
|
0298 (0.186–0.477)
|
< 0.001
|
0.370 (0.215–0.638)
|
< 0.001
|
|
IMRT (No vs Yes)
|
0.480 (0.303–0.759)
|
0.002
|
0.785 (0.461–1.336)
|
0.371
|
|
No. of bone metastasis (≤ 5 vs > 5)
|
0.503 (0.316–0.800)
|
0.004
|
0.597 (0.383–0.930)
|
0.053
|
|
RT to bone metastases (No vs Yes)
|
0.988 (0.620–1.577)
|
0.961
| | |
|
Overall Survival
|
|
Age (≤ 50 vs > 50)
|
1.600 (1.009–2.537)
|
0.046
|
1.484 (0.929–2.372)
|
0.099
|
|
Sex (Female vs Male)
|
1.010 (0.572–1.781)
|
0.973
| | |
|
Chemotherapy cycles (< 4 vs ≥ 4)
|
0.269 (0.170–0.425)
|
< 0.001
|
0.379 (0.224–0.639)
|
< 0.001
|
|
IMRT (No vs Yes)
|
0.374 (0.235–0.595)
|
< 0.001
|
0.624 (0.369–1.054)
|
0.078
|
|
No. of bone metastasis (≤ 5 vs > 5)
|
0.449 (0.282–0.715)
|
0.001
|
0.567 (0.352–0.915)
|
0.020
|
|
RT to bone metastases (No vs Yes)
|
0.914 (0.572–1.459)
|
0.706
| | |
